Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b study of surabgene lomparvovec versus ranibizumab in neovascular age-related macular degeneration
2024-512298-28-00Phase 4Authorised
- Sponsor
- AbbVie Inc.
- Start
- Dec 2025
- Modality
- Gene Therapies
- Countries
- 19
01
Overview
Phase 4, randomised, single-blind trial of surabgene lomparvovec in exudative macular degeneration (2 arms), sponsored by AbbVie Inc. Primary endpoint: Annualized intravitreal anti-VEGF injection rate through Week 54. Planned start Dec 2025; status: authorised.
02
Drugs
surabgene lomparvovec
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2024-512298-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512298-28-00.